The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV

S. Adrian, A. Scherzinger, A. Sanyal, J. E. Lake, J. Falutz, M. P. Dubé, T. Stanley, S. Grinspoon, J. C. Mamputu, C. Marsolais, T. T. Brown, K. M. Erlandson

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Tesamorelin, a growth hormone-releasing hormone analogue, decreases visceral adipose tissue in people living with HIV, however, the effects on skeletal muscle fat and area are unknown. OBJECTIVES: The goals of this exploratory secondary analysis were to determine the effects of tesamorelin on muscle quality (density) and quantity (area). DESIGN: Secondary, exploratory analysis of two previously completed randomized (2:1), clinical trials. SETTING: U.S. and Canadian sites. PARTICIPANTS: People living with HIV and with abdominal obesity. Tesamorelin participants were restricted to responders (visceral adipose tissue decrease ≥8%). INTERVENTION: Tesamorelin or placebo. MEASUREMENTS: Computed tomography scans (at L4-L5) were used to quantify total and lean density (Hounsfield Units, HU) and area (centimeters2) of four trunk muscle groups using a semi-automatic segmentation image analysis program. Differences between muscle area and density before and after 26 weeks of tesamorelin or placebo treatment were compared and linear regression models were adjusted for baseline and treatment arm. RESULTS: Tesamorelin responders (n=193) and placebo (n=148) participants with available images were similar at baseline; most were Caucasian (83%) and male (87%). In models adjusted for baseline differences and treatment arm, tesamorelin was associated with significantly greater increases in density of four truncal muscle groups (coefficient 1.56-4.86 Hounsfield units; all p<0.005), and the lean anterolateral/abdominal and rectus muscles (1.39 and 1.78 Hounsfield units; both p<0.005) compared to placebo. Significant increases were also seen in total area of the rectus and psoas muscles (0.44 and 0.46 centimeters2; p<0.005), and in the lean muscle area of all four truncal muscle groups (0.64-1.08 centimeters2; p<0.005). CONCLUSIONS: Among those with clinically significant decrease in visceral adipose tissue on treatment, tesamorelin was effective in increasing skeletal muscle area and density. Long term effectiveness of tesamorelin among people with and without HIV, and the impact of these changes in daily life should be further studied.

Original languageEnglish (US)
Pages (from-to)154-159
Number of pages6
JournalThe Journal of frailty & aging
Volume8
Issue number3
DOIs
StatePublished - Jan 1 2019

Fingerprint

Growth Hormone-Releasing Hormone
Fats
HIV
Muscles
Intra-Abdominal Fat
Placebos
Linear Models
Skeletal Muscle
Psoas Muscles
tesamorelin
Abdominal Muscles
Abdominal Obesity
Therapeutics
Tomography
Clinical Trials

Keywords

  • frailty
  • IGF-1
  • Muscle quality
  • sarcopenia
  • visceral adipose tissue

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Adrian, S., Scherzinger, A., Sanyal, A., Lake, J. E., Falutz, J., Dubé, M. P., ... Erlandson, K. M. (2019). The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. The Journal of frailty & aging, 8(3), 154-159. https://doi.org/10.14283/jfa.2018.45

The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. / Adrian, S.; Scherzinger, A.; Sanyal, A.; Lake, J. E.; Falutz, J.; Dubé, M. P.; Stanley, T.; Grinspoon, S.; Mamputu, J. C.; Marsolais, C.; Brown, T. T.; Erlandson, K. M.

In: The Journal of frailty & aging, Vol. 8, No. 3, 01.01.2019, p. 154-159.

Research output: Contribution to journalArticle

Adrian, S, Scherzinger, A, Sanyal, A, Lake, JE, Falutz, J, Dubé, MP, Stanley, T, Grinspoon, S, Mamputu, JC, Marsolais, C, Brown, TT & Erlandson, KM 2019, 'The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV', The Journal of frailty & aging, vol. 8, no. 3, pp. 154-159. https://doi.org/10.14283/jfa.2018.45
Adrian, S. ; Scherzinger, A. ; Sanyal, A. ; Lake, J. E. ; Falutz, J. ; Dubé, M. P. ; Stanley, T. ; Grinspoon, S. ; Mamputu, J. C. ; Marsolais, C. ; Brown, T. T. ; Erlandson, K. M. / The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. In: The Journal of frailty & aging. 2019 ; Vol. 8, No. 3. pp. 154-159.
@article{3b0b679facdc4ee5bb09e10c3a7b625b,
title = "The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV",
abstract = "BACKGROUND: Tesamorelin, a growth hormone-releasing hormone analogue, decreases visceral adipose tissue in people living with HIV, however, the effects on skeletal muscle fat and area are unknown. OBJECTIVES: The goals of this exploratory secondary analysis were to determine the effects of tesamorelin on muscle quality (density) and quantity (area). DESIGN: Secondary, exploratory analysis of two previously completed randomized (2:1), clinical trials. SETTING: U.S. and Canadian sites. PARTICIPANTS: People living with HIV and with abdominal obesity. Tesamorelin participants were restricted to responders (visceral adipose tissue decrease ≥8{\%}). INTERVENTION: Tesamorelin or placebo. MEASUREMENTS: Computed tomography scans (at L4-L5) were used to quantify total and lean density (Hounsfield Units, HU) and area (centimeters2) of four trunk muscle groups using a semi-automatic segmentation image analysis program. Differences between muscle area and density before and after 26 weeks of tesamorelin or placebo treatment were compared and linear regression models were adjusted for baseline and treatment arm. RESULTS: Tesamorelin responders (n=193) and placebo (n=148) participants with available images were similar at baseline; most were Caucasian (83{\%}) and male (87{\%}). In models adjusted for baseline differences and treatment arm, tesamorelin was associated with significantly greater increases in density of four truncal muscle groups (coefficient 1.56-4.86 Hounsfield units; all p<0.005), and the lean anterolateral/abdominal and rectus muscles (1.39 and 1.78 Hounsfield units; both p<0.005) compared to placebo. Significant increases were also seen in total area of the rectus and psoas muscles (0.44 and 0.46 centimeters2; p<0.005), and in the lean muscle area of all four truncal muscle groups (0.64-1.08 centimeters2; p<0.005). CONCLUSIONS: Among those with clinically significant decrease in visceral adipose tissue on treatment, tesamorelin was effective in increasing skeletal muscle area and density. Long term effectiveness of tesamorelin among people with and without HIV, and the impact of these changes in daily life should be further studied.",
keywords = "frailty, IGF-1, Muscle quality, sarcopenia, visceral adipose tissue",
author = "S. Adrian and A. Scherzinger and A. Sanyal and Lake, {J. E.} and J. Falutz and Dub{\'e}, {M. P.} and T. Stanley and S. Grinspoon and Mamputu, {J. C.} and C. Marsolais and Brown, {T. T.} and Erlandson, {K. M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.14283/jfa.2018.45",
language = "English (US)",
volume = "8",
pages = "154--159",
journal = "The Journal of frailty & aging",
issn = "2260-1341",
publisher = "Serdi Publishing Company",
number = "3",

}

TY - JOUR

T1 - The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV

AU - Adrian, S.

AU - Scherzinger, A.

AU - Sanyal, A.

AU - Lake, J. E.

AU - Falutz, J.

AU - Dubé, M. P.

AU - Stanley, T.

AU - Grinspoon, S.

AU - Mamputu, J. C.

AU - Marsolais, C.

AU - Brown, T. T.

AU - Erlandson, K. M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - BACKGROUND: Tesamorelin, a growth hormone-releasing hormone analogue, decreases visceral adipose tissue in people living with HIV, however, the effects on skeletal muscle fat and area are unknown. OBJECTIVES: The goals of this exploratory secondary analysis were to determine the effects of tesamorelin on muscle quality (density) and quantity (area). DESIGN: Secondary, exploratory analysis of two previously completed randomized (2:1), clinical trials. SETTING: U.S. and Canadian sites. PARTICIPANTS: People living with HIV and with abdominal obesity. Tesamorelin participants were restricted to responders (visceral adipose tissue decrease ≥8%). INTERVENTION: Tesamorelin or placebo. MEASUREMENTS: Computed tomography scans (at L4-L5) were used to quantify total and lean density (Hounsfield Units, HU) and area (centimeters2) of four trunk muscle groups using a semi-automatic segmentation image analysis program. Differences between muscle area and density before and after 26 weeks of tesamorelin or placebo treatment were compared and linear regression models were adjusted for baseline and treatment arm. RESULTS: Tesamorelin responders (n=193) and placebo (n=148) participants with available images were similar at baseline; most were Caucasian (83%) and male (87%). In models adjusted for baseline differences and treatment arm, tesamorelin was associated with significantly greater increases in density of four truncal muscle groups (coefficient 1.56-4.86 Hounsfield units; all p<0.005), and the lean anterolateral/abdominal and rectus muscles (1.39 and 1.78 Hounsfield units; both p<0.005) compared to placebo. Significant increases were also seen in total area of the rectus and psoas muscles (0.44 and 0.46 centimeters2; p<0.005), and in the lean muscle area of all four truncal muscle groups (0.64-1.08 centimeters2; p<0.005). CONCLUSIONS: Among those with clinically significant decrease in visceral adipose tissue on treatment, tesamorelin was effective in increasing skeletal muscle area and density. Long term effectiveness of tesamorelin among people with and without HIV, and the impact of these changes in daily life should be further studied.

AB - BACKGROUND: Tesamorelin, a growth hormone-releasing hormone analogue, decreases visceral adipose tissue in people living with HIV, however, the effects on skeletal muscle fat and area are unknown. OBJECTIVES: The goals of this exploratory secondary analysis were to determine the effects of tesamorelin on muscle quality (density) and quantity (area). DESIGN: Secondary, exploratory analysis of two previously completed randomized (2:1), clinical trials. SETTING: U.S. and Canadian sites. PARTICIPANTS: People living with HIV and with abdominal obesity. Tesamorelin participants were restricted to responders (visceral adipose tissue decrease ≥8%). INTERVENTION: Tesamorelin or placebo. MEASUREMENTS: Computed tomography scans (at L4-L5) were used to quantify total and lean density (Hounsfield Units, HU) and area (centimeters2) of four trunk muscle groups using a semi-automatic segmentation image analysis program. Differences between muscle area and density before and after 26 weeks of tesamorelin or placebo treatment were compared and linear regression models were adjusted for baseline and treatment arm. RESULTS: Tesamorelin responders (n=193) and placebo (n=148) participants with available images were similar at baseline; most were Caucasian (83%) and male (87%). In models adjusted for baseline differences and treatment arm, tesamorelin was associated with significantly greater increases in density of four truncal muscle groups (coefficient 1.56-4.86 Hounsfield units; all p<0.005), and the lean anterolateral/abdominal and rectus muscles (1.39 and 1.78 Hounsfield units; both p<0.005) compared to placebo. Significant increases were also seen in total area of the rectus and psoas muscles (0.44 and 0.46 centimeters2; p<0.005), and in the lean muscle area of all four truncal muscle groups (0.64-1.08 centimeters2; p<0.005). CONCLUSIONS: Among those with clinically significant decrease in visceral adipose tissue on treatment, tesamorelin was effective in increasing skeletal muscle area and density. Long term effectiveness of tesamorelin among people with and without HIV, and the impact of these changes in daily life should be further studied.

KW - frailty

KW - IGF-1

KW - Muscle quality

KW - sarcopenia

KW - visceral adipose tissue

UR - http://www.scopus.com/inward/record.url?scp=85068795548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068795548&partnerID=8YFLogxK

U2 - 10.14283/jfa.2018.45

DO - 10.14283/jfa.2018.45

M3 - Article

C2 - 31237318

AN - SCOPUS:85068795548

VL - 8

SP - 154

EP - 159

JO - The Journal of frailty & aging

JF - The Journal of frailty & aging

SN - 2260-1341

IS - 3

ER -